Norway: Teva Norway AS v. Astrazeneca Ab, District Court of Olso, 13-189803TVI-OTIR/04, 27 June 2014
February 19, 2015
The Oslo District Court held that the expired Norwegian patent 306452 ("452 Patent") was invalid due to lack of inventive step, which implied that its supplementary protection certificate SPC014 was invalid as well. The court also found the 176 Patent invalid.
A full summary of this case has been published on Kluwer IP Law.
Comments (0)
Your email address will not be published.
Become a contributor!
Interested in contributing? Submit your proposal for a blog post now and become a part of our legal community!
Contact Editorial Guidelines
You may also like
June 24, 2025